Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Visual Field and Quality-of-Life Change in the Treatment for Advanced Glaucoma Study.

Ophthalmology·2026
Same author

Assessment of the level of harm resulting from glaucoma progression due to review delay.

Eye (London, England)·2025
Same author

Emerging perspectives in quality of life after trabeculectomy surgery.

Eye (London, England)·2025
Same author

Which glaucoma patients should be monitored at home and exploration of clinician perceptions on home monitoring? a survey of glaucoma specialists in the UK.

BMJ open·2024
Same author

Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records.

Ophthalmology. Glaucoma·2024
Same author

Feasibility of in-home monitoring for people with glaucoma: the I-TRAC mixed-methods study.

Health technology assessment (Winchester, England)·2024

Related Experiment Videos

Outcome of repeat trabeculectomies.

Carpi Olali1, Alan P Rotchford, Anthony J King

  • 1Department of Ophthalmology and Visual Sciences, Nottingham University Hospital, Nottingham.

Clinical & Experimental Ophthalmology
|March 29, 2012
PubMed
Summary

Repeat trabeculectomy with mitomycin C effectively controls intraocular pressure (IOP) in most patients after failed initial surgery. However, a notable percentage experienced vision loss, indicating a need for careful patient selection and monitoring.

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Glaucoma Surgery
  • Surgical Outcomes

Background:

  • Trabeculectomy is a common glaucoma surgery.
  • Repeat trabeculectomy is considered when initial surgery fails.
  • Mitomycin C is an antifibrotic agent used to enhance surgical success.

Purpose of the Study:

  • To evaluate the efficacy of repeat trabeculectomy augmented with mitomycin C.
  • To assess outcomes in patients with prior failed trabeculectomy.
  • To analyze intraocular pressure control and visual function post-surgery.

Main Methods:

  • A consecutive cohort of 50 patients undergoing repeat trabeculectomy with mitomycin C.
  • Data collected included demographics, clinical findings, and follow-up visits.
  • Key outcome measures were intraocular pressure (IOP) control, visual acuity, and visual field progression.

Main Results:

  • 82% of patients achieved an IOP ≤21 mmHg with a 20% reduction at 12 months.
  • 88% achieved qualified success (IOP ≤21 mmHg and ≥6 mmHg reduction) at 1 year.
  • While visual acuity remained stable on average, 22% lost ≥2 Snellen lines, with no significant change in mean deviation.

Conclusions:

  • Repeat trabeculectomy with mitomycin C is effective for IOP control in most patients.
  • This procedure can prevent further visual deterioration in the majority of cases.
  • A significant proportion of patients experienced visual loss, highlighting potential risks.